{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-23-000007","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.268208+00:00","generated_at":"2026-06-19T00:34:23.377520+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Amphastar Pharmaceuticals amends bylaws to update director nomination procedures and adopt forum selection clause","bullets":["Board approved Amended and Restated Bylaws on Feb 23, 2023.","New requirement for stockholders to deliver evidence of compliance with Rule 14a-19 no later than five business days before meeting.","Adopted forum selection provision for claims under the Securities Act of 1933.","Updated provisions on directors, committees, officers, and conformed to Delaware General Corporation Law."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-23-000007","json":"https://secwatch.observer/filing/0001297184-23-000007.json","markdown":"https://secwatch.observer/filing/0001297184-23-000007.md","text":"https://secwatch.observer/filing/0001297184-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000007/0001297184-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000007/amph-20230223x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:34:23.377520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"919cab5b2ab20760e25bedf220cac2478dd1a1bc","claim":"Amphastar Pharmaceuticals, Inc.: Approved Amended and Restated Bylaws revising director nomination and stockholder proposal procedures, stockholder meeting procedures, director/committee/officer provisions, and adding a forum selection clause (effective 2023-02-23).","evidence_excerpt":"On February 23, 2023, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000007/0001297184-23-000007-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-23"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}